| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
No direct pharmacological target; stable isotope-labeled internal standard for mass spectrometry. Unlabeled 3-methyl-L-histidine is a biomarker of myofibrillar protein turnover (from skeletal muscle actin and myosin) and dietary meat intake.
|
|---|---|
| ln Vitro |
As deuterated internal standard, not biologically active. Unlabeled 3-methyl-L-histidine is an endogenous amino acid formed by post-translational methylation of histidine residues in actin and myosin. Released during protein degradation, not reincorporated, making it a specific biomarker for myofibrillar protein breakdown. Also biomarker for meat consumption (especially chicken) and soy products. Elevated urinary levels associated with increased muscle protein turnover (cachexia, trauma, sepsis, muscular dystrophy).
|
| ln Vivo |
No direct in vivo activity for labeled compound; used as internal standard. Unlabeled 3-methyl-L-histidine is an endogenous marker of myofibrillar protein degradation. In animal models, urinary excretion correlates with muscle protein breakdown rates, used to study effects of nutrition, exercise, disease (cancer cachexia, sepsis, burn injury), and drugs on muscle protein turnover. Decreased in muscle atrophy, increased in muscle wasting.
|
| Enzyme Assay |
No specific binding protocol; used as internal standard for LC-MS/MS. (1) Prepare calibration standards in blank plasma/serum/urine with unlabeled 3-methyl-L-histidine (10-10,000 ng/mL) and fixed concentration of 3-Methyl-L-histidine-d3 (100-500 ng/mL). (2) Protein precipitation: add 3-5 vol ice-cold acetonitrile/0.1% formic acid to 50-100 uL sample. (3) Centrifuge, evaporate supernatant, reconstitute in mobile phase (0.1% formic acid in water/acetonitrile 90:10). (4) HILIC column, ESI-MS/MS positive mode: MRM m/z 170→96 (unlabeled), m/z 173→99 (d3).
|
| Cell Assay |
(1) For myotube studies: seed C2C12 differentiated myotubes in 6-well plates. (2) For protein degradation: label with 14C-histidine for 24 h, wash, add unlabeled medium with/without test compounds (dexamethasone, TNF-alpha, serum deprivation). (3) Collect medium at 0,6,12,24 h, add 3-Methyl-L-histidine-d3 as IS, measure 3-methyl-L-histidine by LC-MS/MS. (4) Cell viability: treat myotubes with labeled compound 0.1-500 uM for 48 h, MTT; non-toxic.
|
| Animal Protocol |
(1) For muscle turnover: use 6-8 week old male SD rats (200-250 g) or C57BL/6 mice (20-25 g). (2) For cachexia: induce muscle wasting by tumor implantation (C26 colon carcinoma), sepsis (CLP), or burn injury. (3) Collect 24-h urine at baseline and days 3,7,14 using metabolic cages. (4) To 50-100 uL urine, add 3-Methyl-L-histidine-d3 (500 ng/mL). (5) Dilute urine 10-50 fold, perform LC-MS/MS. (6) Normalize to creatinine (Jaffe's method). (7) For dietary studies: feed defined diets (chicken, beef, soy) for 7 days, collect urine, measure 3-methyl-L-histidine. (8) At endpoint, collect gastrocnemius and soleus muscles for weight and histology.
|
| ADME/Pharmacokinetics |
3-Methyl-L-histidine-d3 is supplied as light yellow to light brown solid powder. Prepare stock in water or 0.1% formic acid at 0.5-1 mg/mL. For LC-MS use, dilute to 10-1000 ng/mL in 0.1% formic acid. Storage: powder at -20degC for 3 years; solution at -20degC for 6 months, -80degC for 1 year. Solubility: water ≥10 mg/mL. Stable at neutral pH.
|
| Toxicity/Toxicokinetics |
Non-toxic as stable isotope-labeled endogenous metabolite used at trace levels (ng-ug/mL). Unlabeled 3-methyl-L-histidine is endogenous, present in plasma (0.1-1 uM) and urine (10-200 umol/g creatinine) in healthy individuals. No toxicity reported for labeled or unlabeled compound. For research use only.
|
| References | |
| Additional Infomation |
3-Methyl-L-histidine-d3 is a deuterium-labeled stable isotope internal standard for accurate quantification of 3-methyl-L-histidine by GC-MS or LC-MS. 3-Methyl-L-histidine is formed by post-translational methylation of specific histidine residues in actin (His73 in fast-twitch muscle) and myosin (His1). Not reutilized for protein synthesis, excreted unchanged in urine, making it a specific biomarker for myofibrillar protein breakdown. Elevated in cachexia, sepsis, burns, trauma, muscular dystrophy, and after dietary meat intake (especially chicken). Not a drug; strictly for research and analytical use.
|
| Molecular Formula |
C7H11N3O2
|
|---|---|
| Molecular Weight |
172.199626207352
|
| Exact Mass |
172.103
|
| CAS # |
144868-18-8
|
| Related CAS # |
3-Methyl-L-histidine;368-16-1
|
| PubChem CID |
162623739
|
| Appearance |
Light yellow to light brown solid powder
|
| LogP |
-3.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
174
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC([C@H](CC1=CN=CN1C([2H])([2H])[2H])N)=O
|
| InChi Key |
JDHILDINMRGULE-FYFSCIFKSA-N
|
| InChi Code |
InChI=1S/C7H11N3O2/c1-10-4-9-3-5(10)2-6(8)7(11)12/h3-4,6H,2,8H2,1H3,(H,11,12)/t6-/m0/s1/i1D3
|
| Chemical Name |
(2S)-2-amino-3-[3-(trideuteriomethyl)imidazol-4-yl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8072 mL | 29.0360 mL | 58.0720 mL | |
| 5 mM | 1.1614 mL | 5.8072 mL | 11.6144 mL | |
| 10 mM | 0.5807 mL | 2.9036 mL | 5.8072 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
